Attached files
file | filename |
---|---|
EX-31.1 - China Dongfang Healthcare Group Inc. | v202497_ex31-1.htm |
EX-32.2 - China Dongfang Healthcare Group Inc. | v202497_ex32-2.htm |
EX-32.1 - China Dongfang Healthcare Group Inc. | v202497_ex32-1.htm |
EX-31.2 - China Dongfang Healthcare Group Inc. | v202497_ex31-2.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the quarterly period ended September 30, 2010.
or
¨
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
For
the transition period from _____________________ to
____________________________
|
Commission
File Number: 000-54063
China
Dongfang Healthcare Group Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
46-0525216
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
No.
8, Shian South Road, Shijing Street, Baiyun District,
Guangzhou
City, People’s Republic of China 510430
|
(Address
of principal executive offices) (Zip
Code)
|
(011)
86 20 611 60111
|
(Registrant’s
telephone number, including area
code)
|
N/A
|
(Former
name, former address and former fiscal year, if
changed
since last report)
|
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes ¨
No x
Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).
Yes ¨ No ¨
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨
|
Smaller
reporting company x
|
(Do
not check if a
|
|||
smaller
reporting company)
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes ¨ No x
Indicate
the number of shares outstanding of each of the issuer’s classes of common
stock, as of the latest practicable date: 21,000,000 shares of Common Stock, par
value $0.0001, as of November 10, 2010.
CHINA
DONGFANG HEALTHCARE GROUP INC.
QUARTERLY
REPORT ON FORM 10-Q
FOR
THE QUARTER ENDED SEPTEMBER 30, 2010
TABLE
OF CONTENTS
PART
I - FINANCIAL INFORMATION
|
1
|
||
Item
1.
|
Condensed
Consolidated Financial Statements
|
1
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
12
|
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
28
|
|
Item
4.
|
Controls
and Procedures
|
28
|
|
PART
II - OTHER INFORMATION
|
29
|
||
Item
1.
|
Legal
Proceedings
|
29
|
|
Item
1A.
|
Risk
Factors
|
29
|
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
29
|
|
Item
3.
|
Defaults
Upon Senior Securities
|
30
|
|
Item
4.
|
Submissions
of Matters to a Vote of Security Holders
|
30
|
|
Item
6.
|
Exhibits
|
30
|
|
SIGNATURES
|
32
|
* * *
In this
quarterly report, unless otherwise specified or the context otherwise requires,
the terms “we” “us,” “our,” and the “Company” refer to China Dongfang Healthcare
Group Inc. and our consolidated subsidiaries taken together as a
whole.
Pursuant
to Item 10(f) of Regulation S-K promulgated under the Securities Act of 1933, we
have elected to comply throughout this quarterly report with the scaled
disclosure requirements applicable to “smaller reporting
companies.” Except as specifically included in the quarterly report,
items not required by the scaled disclosure requirements have been
omitted.
i
PART
I - FINANCIAL INFORMATION
Item
1.
|
Financial
Statements.
|
CHINA
DONGFANG HEALTHCARE GROUP INC.
CONDENSED BALANCE
SHEETS
September
30,
|
December
31,
|
|||||||
2010
|
2009
|
|||||||
(Consolidated
|
(Combined)
|
|||||||
and
unaudited)
|
||||||||
ASSETS
|
||||||||
CURRENT
ASSETS
|
||||||||
Cash
and cash equivalents
|
$ | 1,250,402 | $ | 1,420,407 | ||||
Accounts
receivable, net
|
160,299 | 100,909 | ||||||
Prepaid
expenses and other current assets
|
553,217 | 455,322 | ||||||
Inventories,
net
|
38,079 | 23,554 | ||||||
Total
Current Assets
|
2,001,997 | 2,000,192 | ||||||
PROPERTY
AND EQUIPMENT, NET
|
5,767,649 | 6,223,560 | ||||||
LAND
USE RIGHTS, NET
|
1,931,282 | 1,922,617 | ||||||
TOTAL
ASSETS
|
$ | 9,700,928 | $ | 10,146,369 | ||||
LIABILITIES AND STOCKHOLDERS'
EQUITY
|
||||||||
CURRENT
LIABILITIES
|
||||||||
Accounts
payable
|
$ | 375,921 | $ | 441,440 | ||||
Other
payables and accrued expenses
|
474,102 | 386,720 | ||||||
Note
payable
|
- | 731,294 | ||||||
Income
tax payable
|
12,400 | 12,148 | ||||||
Due
to a stockholder
|
540,388 | 337,423 | ||||||
Due
to a related company
|
205,756 | 201,572 | ||||||
Total
Current Liabilities
|
1,608,567 | 2,110,597 | ||||||
LONG-TERM
LIABILITIES
|
||||||||
Due
to a stockholder
|
3,045,640 | 3,510,209 | ||||||
Total
Long-term Liabilities
|
3,045,640 | 3,510,209 | ||||||
TOTAL
LIABILITIES
|
4,654,207 | 5,620,806 | ||||||
COMMITMENTS
AND CONTINGENCIES
|
- | - | ||||||
STOCKHOLDERS'
EQUITY
|
||||||||
Preferred
stock ($0.0001 par value, 20,000,000 shares authorized, no shares issued
as of September 30, 2010 and December 31, 2009)
|
- | - | ||||||
Common
stock ($0.0001 par value, 200,000,000 shares authorized, 21,000,000 shares
issued and outstanding as of September 30, 2010 and December 31,
2009)
|
2,100 | 2,100 | ||||||
Stock
subscription receivable
|
- | (466,709 | ) | |||||
Additional
paid-in capital
|
1,181,149 | 1,177,580 | ||||||
Retained
earnings
|
||||||||
Unappropriated
|
3,354,495 | 3,406,552 | ||||||
Appropriated
|
25,781 | 25,781 | ||||||
Accumulated
other comprehensive income
|
483,196 | 380,259 | ||||||
Total
Stockholders' Equity
|
5,046,721 | 4,525,563 |
The
accompanying notes are an integral part of these unaudited condensed
consolidated financial statements
1
CHINA
DONGFANG HEALTHCARE GROUP INC.
CONDENSED
STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
(UNAUDITED)
Three
months ended September 30,
|
Nine
months ended September 30,
|
|||||||||||||||
2010
|
2009
|
2010
|
2009
|
|||||||||||||
(Consolidated)
|
(Combined)
|
(Consolidated)
|
(Combined)
|
|||||||||||||
PATIENT
SERVICE REVENUE
|
||||||||||||||||
Patient
revenue
|
$ | 799,086 | $ | 912,330 | $ | 2,320,705 | $ | 2,269,138 | ||||||||
Sale
of medicine
|
290,005 | 300,051 | 772,174 | 762,752 | ||||||||||||
Total
Patient Service Revenue
|
1,089,091 | 1,212,381 | 3,092,879 | 3,031,890 | ||||||||||||
COST
OF REVENUE
|
||||||||||||||||
Cost
of patient revenue
|
355,522 | 474,248 | 1,263,124 | 1,147,854 | ||||||||||||
Cost
of medicine
|
149,928 | 66,209 | 311,205 | 234,772 | ||||||||||||
Depreciation
|
145,273 | 142,284 | 431,156 | 424,142 | ||||||||||||
Total
Cost of Revenue
|
650,723 | 682,741 | 2,005,485 | 1,806,768 | ||||||||||||
GROSS
PROFIT
|
438,368 | 529,640 | 1,087,394 | 1,225,122 | ||||||||||||
OPERATING
EXPENSES
|
||||||||||||||||
Selling,
general and administrative expenses
|
218,094 | 170,042 | 606,696 | 531,223 | ||||||||||||
Professional
fees
|
35,313 | - | 74,138 | 1,169 | ||||||||||||
Amortization
of land use rights
|
10,294 | 10,203 | 30,719 | 30,602 | ||||||||||||
Depreciation
|
88,542 | 90,140 | 279,024 | 270,157 | ||||||||||||
Total
Operating Expenses
|
352,243 | 270,385 | 990,577 | 833,151 | ||||||||||||
INCOME
FROM OPERATIONS
|
86,125 | 259,255 | 96,817 | 391,971 | ||||||||||||
OTHER
INCOME (EXPENSE)
|
||||||||||||||||
Interest
income
|
1,001 | - | 6,852 | - | ||||||||||||
Interest
paid to a stockholder
|
(44,302 | ) | (40,054 | ) | (132,035 | ) | (127,561 | ) | ||||||||
Interest
expense on note payable
|
- | - | (20,122 | ) | - | |||||||||||
Imputed
interest
|
(864 | ) | (2,391 | ) | (3,569 | ) | (7,170 | ) | ||||||||
Total
Expense, net
|
(44,165 | ) | (42,445 | ) | (148,874 | ) | (134,731 | ) | ||||||||
NET
INCOME (LOSS) BEFORE TAXES
|
41,960 | 216,810 | (52,057 | ) | 257,240 | |||||||||||
Income
tax expense
|
- | - | - | - | ||||||||||||
NET
INCOME (LOSS)
|
41,960 | 216,810 | (52,057 | ) | 257,240 | |||||||||||
OTHER
COMPREHENSIVE INCOME
|
||||||||||||||||
Foreign
currency translation gains
|
84,895 | 4,299 | 102,937 | 9,899 | ||||||||||||
COMPREHENSIVE
INCOME
|
$ | 126,855 | $ | 221,109 | $ | 50,880 | $ | 267,139 | ||||||||
Net
income (loss) per share -basic and diluted
|
$ | 0.00 | $ | 0.01 | $ | (0.00 | ) | $ | 0.01 | |||||||
Weighted
average number of shares outstanding during the period - basic
and diluted
|
21,000,000 | 21,000,000 | 21,000,000 | 21,000,000 |
The
accompanying notes are an integral part of these unaudited condensed
consolidated financial statements
2
CHINA
DONGFANG HEALTHCARE GROUP INC.
CONDENSED
STATEMENTS OF CASH FLOWS FOR THE
NINE MONTHS ENDED SEPTEMBER
30, 2010 AND 2009 (UNAUDITED)
2010
|
2009
|
|||||||
(Consolidated)
|
(Combined)
|
|||||||
CASH
FLOWS FROM OPERATING ACTIVITIES
|
||||||||
Net
(loss) income
|
$ | (52,057 | ) | $ | 257,240 | |||
Adjusted
to reconcile net (loss) income to cash provided by operating
activities:
|
||||||||
Depreciation
- cost of revenue
|
431,156 | 424,142 | ||||||
Depreciation
|
279,024 | 270,157 | ||||||
Amortization
of land use rights
|
30,719 | 30,602 | ||||||
Imputed
interest
|
3,569 | 7,170 | ||||||
Changes
in operating assets and liabilities
|
||||||||
(Increase)
decrease in:
|
||||||||
Accounts
receivable
|
(59,390 | ) | (201,290 | ) | ||||
Prepaid
expenses and other current assets
|
(97,895 | ) | (27,704 | ) | ||||
Inventories
|
(14,525 | ) | (7,440 | ) | ||||
Increase
(decrease) in:
|
||||||||
Accounts
payable
|
27,205 | (118,958 | ) | |||||
Other
payables and accrued expenses
|
(5,342 | ) | (252,018 | ) | ||||
Net
cash provided by operating activities
|
542,464 | 381,901 | ||||||
CASH
FLOWS FROM INVESTING ACTIVITIES
|
||||||||
Purchase
of property and equipment
|
(135,181 | ) | (167,781 | ) | ||||
Net
cash used in investing activities
|
(135,181 | ) | (167,781 | ) | ||||
CASH
FLOWS FROM FINANCING ACTIVITIES
|
||||||||
Proceeds
from issuance of common stock
|
466,709 | 43,829 | ||||||
Repayment
of note payable
|
(731,294 | ) | - | |||||
Decrease
in due to a stockholder
|
(261,604 | ) | (376,922 | ) | ||||
Increase
in due to a related company
|
4,184 | 194,040 | ||||||
Net
cash used in financing activities
|
(522,005 | ) | (139,053 | ) | ||||
EFFECT
OF EXCHANGE RATE ON CASH
|
(55,283 | ) | (11,318 | ) | ||||
NET
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
|
(170,005 | ) | 63,749 | |||||
CASH
AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
|
1,420,407 | 192,266 | ||||||
CASH
AND CASH EQUIVALENTS AT END OF PERIOD
|
$ | 1,250,402 | $ | 256,015 | ||||
SUPPLEMENTAL
DISCLOSURE OF CASH FLOW INFORMATION:
|
||||||||
Cash
paid during the period:
|
||||||||
Interest
expenses on due to a stockholder accrued in previous periods now
paid
|
$ | 176,046 | $ | - | ||||
Interest
expenses on note payable
|
$ | 20,122 | $ | - |
The
accompanying notes are an integral part of these unaudited condensed
consolidated financial statements
3
CHINA
DONGFANG HEALTHCARE GROUP INC.
NOTES TO
THE CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
(UNAUDITED)
1.
|
SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES AND
ORGANIZATION
|
(A) Basic
of presentation
The
accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial information and pursuant to the
rules and regulations of the Securities and Exchange Commission. Accordingly,
they do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements.
In the
opinion of management, the unaudited condensed consolidated financial statements
contain all adjustments consisting only of normal recurring accruals considered
necessary to present fairly the Company's financial position at September 30,
2010, the results of operations for the three and nine months ended September
30, 2010 and 2009 and cash flows for the nine months ended September 30, 2010
and 2009. The results for the three and nine months ended September 30, 2010 are
not necessarily indicative of the results to be expected for the entire fiscal
year ending December 31, 2010.
These
financial statements should be read in conjunction with the audited
combined financial statements of the Company and the notes thereto for the
years ended December 31, 2009 and 2008.
(B)
Organization
China
Dongfang Healthcare Group Inc. (“China Dongfang Healthcare”) was incorporated in
Nevada on September 29, 2009 as a holding company.
Winmark
Group Limited (“Winmark”) was incorporated in the British Virgin Islands (“BVI”)
on August 8, 2008 as a holding company. Winmark established a wholly-owned
foreign enterprise, Guangzhou Shouzhi Medical Institution Management Co. Ltd.
(“Shouzhi”), on November 13, 2009 in the People’s Republic of China (“PRC”) to
provide consulting, investment and technical services to healthcare
organizations in the PRC.
Guangzhou
Dongfang Hospital was incorporated on July 10, 2002 in the PRC as a
not-for-profit organization to provide medical consultation services and sell
medical products to patients in Guangzhou, Guangdong Province, PRC. In August
2009, Guangzhou Dongfang Hospital became a for-profit organization and was
renamed in April 2009 as Guangzhou Dongfang Hospital Co. Ltd. (“GDH”) with right
of operation to February 2020.
On April
30, 2010, China Dongfang Healthcare entered into a share exchange agreement with
Winmark and the stockholders of Winmark in which the stockholders of Winmark
exchanged 100% of the registered and fully paid up capital of Winmark, valued at
$50,000, for 21,000,000 shares of common stock, $0.0001 par value per share, of
China Dongfang Healthcare. Winmark became a wholly owned subsidiary of China
Dongfang Healthcare. As both companies are under common control, the share
exchange involving China Dongfang Healthcare and Winmark is being treated for
accounting purposes as a capital transaction and a reorganization of entities
under common control with China Dongfang Healthcare as the accounting acquirer
and Winmark as the accounting acquiree. The consolidated financial statements
were prepared as if the reorganization occurred at the beginning of the first
period presented.
Accordingly,
these consolidated financial statements include the following:
|
1.
|
The
balance sheet consisting of the net assets of the acquirer and acquiree at
historical cost; and
|
4
|
2.
|
The
statement of operations including the operations of the acquirer and
acquiree for the periods presented.
|
On June
14, 2010, Shouzhi entered into a series of contractual arrangements with GDH and
the sole stockholder of GDH pursuant to which Shouzhi assumed the management of
the business activities of GDH and GDH agreed to pay 100% of its profits to
Shouzhi. Through this arrangement, GDH became a 100% contractually controlled
subsidiary of Shouzhi. Based on these contractual arrangements, the Company
considers GDH to be a Variable Interest Entity (“VIE”) under ASC 810,
"Consolidation of Variable Interest Entities, an Interpretation of ARB No.51"
and Winmark through Shouzhi is the primary beneficiary of GDH (See note 2).
Accordingly, GDH should be consolidated under ASC 810. Immediately prior to the
transactions that were completed on June 14, 2010, the Chief Executive Officer
of the Company controlled GDH as he owned 100% of its registered capital. He
also controlled Shouzhi as he was its executive director and indirectly
controlled 54.3% of the outstanding common stock of its ultimate parent, China
Dongfang Healthcare. As Winmark, Shouzhi and GDH are under common control, the
contractual arrangements have been accounted for as a reorganization of entities
under common control and the consolidated financial statements were prepared as
if the reorganization occurred at the beginning of the first period
presented.
China
Dongfang Healthcare, Winmark, Shouzhi and GDH are hereinafter referred to as
(“the Company”).
(C) Principles
of consolidation and combination
The
accompanying unaudited condensed consolidated financial statements as of and for
the nine months ended September 30, 2010 include the unaudited financial
statements of China Dongfang Healthcare, its wholly owned subsidiaries, Winmark
and Shouzhi, and its contractually controlled affiliate, GDH.
The
accompanying unaudited condensed combined financial statements as of and for the
nine months ended September 30, 2009 include the unaudited financial statements
of Winmark and GDH.
All
significant inter-company accounts and transactions have been eliminated in
consolidation and combination.
(D) Use
of estimates
The
preparation of the financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amount of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
(E) Cash
and cash equivalents
For
purposes of the balance sheets and the statements of cash flows, cash and cash
equivalents include cash on hand and demand deposits with a bank with a maturity
of less than three months.
(F) Accounts
receivable
Accounts
receivable are recorded at the estimated net realizable amounts from PRC
government units and patients. Generally, GDH collects the fees from patients
without any form of governmental healthcare coverage in cash at the time of the
service. Credit will only be given to PRC social insurance organization. The PRC
social insurance organization reimburses the Company on a 30-day cycle and
collection for the Company has historically not been considered to be an area
that exposes the Company to additional risk. As of September 30, 2010 and
December 31, 2009, accounts receivable from the PRC social insurance
organization represents 84% and 83% of total accounts receivable
respectively.
5
For a
patient covered by governmental healthcare programs who visits GDH, GDH will
only include the portion of charges borne by the social insurance organization
in accounts receivable and collects the balance in cash at the time of the
service.
As of
September 30, 2010 and December 31, 2009, the Company considers all its accounts
receivable to be collectible and no provision for doubtful accounts has been
made in the financial statements.
(G) Property
and equipment
Property
and equipment are stated at cost, less accumulated depreciation. Expenditures
for additions, major renewals and betterments are capitalized and expenditures
for maintenance and repairs are charged to expense as incurred.
Depreciation
is provided on a straight-line basis, less estimated residual values over the
assets’ estimated useful lives. The estimated useful lives are as
follows:
Buildings
|
30
Years
|
Medical
equipment
|
10
Years
|
Furniture,
fixtures and equipment
|
5
Years
|
Motor
vehicles
|
5
Years
|
Land use
rights are stated at cost, less accumulated amortization, and are amortized over
50 years from the date of acquisition.
(H) Revenue
recognition
The
Company recognizes revenue over the period the service is performed in
accordance with ASC No. 605, Revenue Recognition in Financial Statements. In
general, ASC No. 605 requires that four basic criteria must be met before
revenue can be recognized: (i) persuasive evidence of an arrangement exists,
(ii) delivery has occurred or services rendered, (iii) the fee is fixed and
determinable, and (iv) collectability is reasonably assured.
The
Company bills for services rendered based upon several methodologies including
established charges, the cost of providing services, predetermined rates per
diagnosis, fixed per diem rates and discount from established
charges.
The
Company derives a significant portion of its revenue from patients who do not
have any form of governmental healthcare coverage. For self-pay or
non-governmental insurance protected inpatients, a minimum deposit of $15 must
be paid by the patients before receiving any medical treatment and will be
replenished when the deposit is used up. The final outstanding fee billed must
be collected before discharge from the hospital. Revenue associated with these
patients is reported at the Company’s gross charges and recognized when the
medical services are provided. For self-pay or non-governmental insurance
protected outpatients, consultation services are usually associated with
subsequent sale of medicine. Fees will be billed on provision of consultation
services and must be collected before dispensing medicine to patients. Revenue
will be recognized when the consultation services are provided. For revenue
derived from treatment of patients covered by governmental programs, fees are
billed on provision of medical treatments and monthly statements will be sent to
state-owned insurance houses for collection of fees. The revenue derived is
reported at gross charges and recognized on provision of medical
services.
The
Company also sells medicine to patients and revenue from these sales is
recognized upon the pharmaceutical drugs being dispensed for use by
patients.
In June
2009, GDH entered into an eight-year exclusive cooperation agreement with a
licensed dentist to jointly organize and operate a dental clinic housed at GDH.
This clinic provides patients with a variety of dental services and medicines.
GDH is responsible for providing dental chairs, treatment units and other
equipment, as well as the medical staff. The parties have agreed to split
revenues from the dental center, and the licensed dentist has agreed to provide
GDH with a minimum amount of revenue each month. The dental clinic has been
operational since June 1, 2009.
6
GDH also
entered into a five-year cooperation agreement in September 2009 with a licensed
physician specializing in surgery to invest in the Guangdong Province Medical
Association Medical Center. The cooperation agreement requires GDH to provide a
facility, equipment and operating permit to be able to treat patients in this
medical center. The licensed physician is responsible for paying utilities,
taxes and security for the medical center, and provided GDH an initial
investment of $29,860. Other expenses are to be allocated to the medical center.
The parties have agreed to split revenues from the medical center depending on
its source and the licensed physician has agreed to provide GDH with a minimum
amount of revenue each year. The medical center has been operational since
September 8, 2009.
The
Company collects the revenues from the dental center and the medical center and
allocates the associated costs to each center by the Company’s charging system
and financial system. The Company recognizes the revenues and the associated
costs from the centers as a gross amount and consolidates the accounts of each
center. The gross profit derived from each center would be allocated between GDH
and the counterparty to the respective cooperation agreement. The profit
allocated to the counterparty would be recorded in the Company’s cost of
revenue.
(I) Income
taxes
The
Company accounts for income taxes under the ASC Topic 740-10-25 (“ASC
740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are
recognized for the future tax consequences attributable to differences between
the consolidated financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or
settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities
of a change in tax rates is recognized as income in the period included the
enactment date.
On
January 1, 2007, the Company adopted the provisions of ASC 740-10-25,
"Accounting for Uncertainty in Income Taxes". ASC 740-10-25 prescribes a
more-likely-than-not threshold for consolidated financial statement recognition
and measurement of a tax position taken (or expected to be taken) in a tax
return. This Interpretation also provides guidance on the recognition of income
tax assets and liabilities, classification of current and deferred income tax
assets and liabilities, accounting for interest and penalties associated with
tax positions, accounting for interest and penalties associated with tax
positions, accounting for income taxes in interim periods and income tax
disclosures. The adoption of ASC 740-10-25 has not resulted in any material
impact on the Company's financial position or results.
(J) Foreign
currency translation
China
Dongfang Healthcare and Winmark maintain their accounting records in their
functional currencies of United States Dollars ("US$") and Hong Kong Dollars
("HK$") respectively, whereas Shouzhi and GDH maintain their accounting records
in their functional currency of Renminbi ("RMB").
Foreign
currency transactions during the year are translated to its functional currency
at the approximate rates of exchange on the dates of transactions. Monetary
assets and liabilities denominated in foreign currencies at the balance sheet
date are translated at the approximate rates of exchange at that date.
Non-monetary assets and liabilities are translated at the rates of exchange
prevailing at the time the asset or liability was acquired. Exchange gains or
losses are recorded in the statement of operations.
The
financial statements of the subsidiaries whose functional currency is HK$ and
RMB are translated into US$ using the closing rate method. The balance sheet
items are translated into US$ using the exchange rates at the respective balance
sheet dates. The capital and various reserves are translated at historical
exchange rates prevailing at the time of the transactions while income and
expenses items are translated at the average exchange rate for the year. All
exchange differences are recorded as a component of accumulated other
comprehensive income within equity.
7
The
exchange rates used to translate amounts in RMB into US$ for the purposes of
preparing the financial statements were as follows:
September 30, 2010
|
December 31,2009
|
|||
Balance
sheet items, except for share capital, additional paid-in capital and
retained earnings, as of year end
|
US$1=HK$7.75
=RMB6.6981
|
US$1=HK$7.75
=RMB6.8372
|
||
Amounts
included in the statements of operations and cash flows for the
year
|
US$1=HK$7.75=
RMB6.8164
|
US$1=HK$7.75
=RMB6.84088
|
The
exchange rate used to translate amounts in HK$ into $US was US$1 = HK$7.75 for
all items in the financial statements.
The
translation difference recorded for the three and nine months ended September
30, 2010 and 2009 were gains of $84,895, $4,299, $102,937 and $9,899
respectively.
No
presentation is made that RMB amounts have been, or would be, converted into US$
at the above rates. Although the Chinese government regulations now allow
convertibility of RMB for current account transactions, significant restrictions
still remain. Hence, such translations should not be construed as a
representation that the RMB could be converted into US$ at that rate or any
other rate.
The value
of RMB against US$ and other currencies may fluctuate and is affected by, among
other things, changes in China’s political and economic conditions, any
significant revaluation of RMB may materially affect the Company’s financial
condition in terms of US$ reporting.
Since HK$
is pegged to US$, there is no significant exposure expected on HK$ transactions
and balances.
(K) Other
comprehensive income
The
foreign currency translation gain or loss resulting from translation of the
financial statements expressed in HK$ and RMB to US$ is reported as other
comprehensive income gain in the statements of operations and stockholders’
equity. Other comprehensive income for the three and nine months ended September
30, 2010 and 2009 was $84,895, $4,299, $102,937 and $9,899
respectively.
(L) Earnings
per share
Earnings
per share in accordance with the provisions of ASC Topic 260, “Earnings Per
Share”, (formerly SFAS No. 128, "Earnings Per Share"). ASC Topic 260 requires
presentation of basic and diluted earnings per share in conjunction with the
disclosure of the methodology used in computing such earnings per share. Basic
earnings per share excludes dilution and is computed by dividing income
available to common stockholders by the weighted average common shares
outstanding during the period. Diluted earnings per share takes into account the
potential dilution that could occur if securities or other
contracts
to issue common stock were exercised and converted into common stock using the
treasury method.
(M) Recent
accounting pronouncements
In
October 2009, the FASB issued ASU 2009-13, “Multiple-Deliverable Revenue
Arrangements”, now codified under FASB ASC Topic 605, “Revenue Recognition”,
(“ASU 2009-13”). ASU 2009-13 requires entities to allocate revenue in an
arrangement using estimated selling prices of the delivered goods and services
based on a selling price hierarchy. The amendments eliminate the residual method
of revenue allocation and require revenue to be allocated using the relative
selling price method. ASU 2009-13 should be applied on a prospective basis for
revenue arrangements entered into or materially modified in fiscal years
beginning on or after June 15, 2010, with early adoption permitted. The
adoption of this statement will not have a material impact on the Company’s
financial position and results of operations.
8
In
December 2009, FASB issued ASU 2009-16 Transfers and Servicing (Topic 860)
Accounting for Transfers of Financial Assets ("ASU 2009-16"). ASU 2009-16 amends
the FASB Accounting Standards Codification for the issuance of FASB Statement
No. 166, Accounting for Transfers of Financial Assets—an amendment of FASB
Statement No. 140. The amendments in ASU 2009-16 improve financial
reporting by eliminating the exceptions for qualifying special-purpose entities
from the consolidation guidance and the exception that permitted sale accounting
for certain mortgage securitizations when a transferor has not surrendered
control over the transferred financial assets. In addition, the amendments
require enhanced disclosures about the risks that a transferor continues to be
exposed to because of its continuing involvement in transferred financial
assets. ASU 2009-16 is effective as of the beginning of each reporting entity's
first annual reporting period that begins after November 15,
2009. The Company does not expect the adoption of ASU 2009-16 to have
a material impact on the Company’s financial position and results of
operations.
In
December 2009, FASB issued ASU 2009-17 Consolidations (Topic 810) Improvements
to Financial Reporting by Enterprises Involved with Variable Interest Entities
("ASU 2009-17"). ASU 2009-17 amends the FASB ASC 810 for the issuance of FASB
Statement No. 167, Amendments to FASB Interpretation No. 46(R). The
amendments in ASU 2009-17 replace the quantitative-based risks and rewards
calculation for determining which enterprise, if any, has a controlling
financial interest in a variable interest entity with an approach focused on
identifying which enterprise has the power to direct the activities of a
variable interest entity that most significantly impact the entity's economic
performance and (1) the obligation to absorb losses of the entity or
(2) the right to receive benefits from the entity. ASU 2009-17 also
requires additional disclosures about an enterprise's involvement in variable
interest entities. ASU 2009-17 is effective as of the beginning of each
reporting entity's first annual reporting period that begins after
November 15, 2009. The Company does not expect the adoption of ASU 2009-17
to have a material impact on the Company’s financial position and results of
operations except that additional disclosures will be made in the financial
statements.
In
January 2010, FASB issued ASU 2010-6 Improving Disclosures about Fair
Measurements ("ASU 2010-6"). ASU 2010-6 provides amendments to ASC Topic
820-10 that require separate disclosure of significant transfers in and out of
Level 1 and Level 2 fair value measurements and the presentation of
separate information regarding purchases, sales, issuances and settlements for
Level 3 fair value measurements. Additionally, ASU 2010-6 provides
amendments to ASC Topic 820-10 that clarify existing disclosures about the level
of disaggregation and inputs and valuation techniques. ASU 2010-6 is effective
for financial statements issued for interim and annual periods ending after
December 15, 2010. The Company does not expect the adoption of ASU 2010-06
to have a material impact on the Company’s financial position and results of
operations.
In
February 2010, FASB issued ASU 2010-9 Subsequent Events (Topic 855) Amendments
to Certain Recognition and Disclosure Requirements ("ASU 2010-9"). ASU 2010-9
amends disclosure requirements within ASC Topic 855-10. An entity that is an SEC
filer is not required to disclose the date through which subsequent events have
been evaluated. This change alleviates potential conflicts between ASC Topic
855-10 and the SEC's requirements. ASU 2010-9 is effective for interim and
annual periods ending after June 15, 2010. The Company does not expect the
adoption of ASU 2010-09 to have a material impact on the Company’s financial
position and results of operations.
In March
2010, FASB issued ASU 2010-11 Scope Exception Related to Embedded Credit
Derivatives (“ASU 2010-11”). ASU 2010-11 clarifies the type of embedded credit
derivative that is exempt from embedded derivative bifurcation requirements.
Only one form of embedded credit derivative qualifies for the exemption—one that
is related only to the subordination of one financial instrument to
another. As a result, entities that have contracts containing an
embedded credit derivative feature in a form other than such subordination may
need to separately account for the embedded credit derivative feature. The
amendments in this Update are effective for each reporting entity at the
beginning of its first fiscal quarter beginning after June 15,
2010. Early adoption is permitted at the beginning of each entity’s
first fiscal quarter beginning after issuance of this Update. The
Company does not expect the adoption of ASU 2010-11 to have a material impact on
the Company’s financial position and results of operations.
9
In April
2010, FASB issued ASU 2010-13 Compensation-Stock Compensation (Topic 718) Effect
of Denominating the Exercise Price of a Share-Based Payment Award in the
Currency of the Market in Which the Underlying Equity Security
Trades. ASU 2010-13 addresses the classification of a share-based
payment award with an exercise price denominated in the currency of a market in
which the underlying equity security trades. Topic 718 is amended to clarify
that a share-based payment award with an exercise price denominated in the
currency of a market in which a substantial portion of the entity’s equity
securities trades shall not be considered to contain a market, performance, or
service condition. Therefore, such an award is not to be classified as a
liability if it otherwise qualifies as equity classification. The amendments in
this Update should be effective for fiscal years, and interim periods within
those fiscal years, beginning on or after December 15, 2010. The
guidance should be applied by recording a cumulative-effect adjustment to the
opening balance of retained earnings for all outstanding awards as of the
beginning of the fiscal year in which the amendments are initially
applied. The Company does not expect the adoption of ASU 2010-13 to
have a material impact on the Company’s financial position and results of
operations.
In July
2010, FASB issued ASU 2010-20 Receivables (Topic 310): Disclosures about the
Credit Quality of Financing Receivables and the Allowance for Credit Losses.
This Update improves the disclosures that an entity provides about the credit
quality of its financing receivables and the related allowance for credit
losses. As a result of these amendments, an entity is required to disaggregate
by portfolio segment or class certain existing disclosures and provide certain
new disclosures about its financing receivables and related allowance for credit
losses. For public entities, the disclosures as of the end of a reporting period
are effective for interim and annual reporting period ending on or after
December 15, 2010. The disclosures about activity that occurs during a reporting
period are effective for interim and annual reporting periods beginning on or
after December 15, 2010. The Company does not expect the adoption of ASU 2010-2
to have a material impact on the Company’s financial position and results of
operations.
In August
2010, FASB issued ASU 2010-21 Accounting for Technical Amendments to Various SEC
Rules and Schedules. Amendments to SEC Paragraphs Pursuant to Release No.
33-9026: Technical Amendments to Rules, Forms, Schedules and Codification of
Financial Reporting Policies. This Accounting Standards Update amends various
SEC paragraphs pursuant to the issuance of Release No. 33-9026: Technical
Amendments to Rules, Forms, Schedules and Codification of Financial Reporting
Policies. The adoption of ASU 2010-21 did not have a material impact on the
Company’s financial statements.
In August
2010, FASB issued ASU 2010-22 Accounting for Various Topics-Technical
Corrections to SEC paragraphs (SEC Update). This Accounting Standards Update
amends various SEC paragraphs based on external comments received and the
issuance of SAB 112, which amends or rescinds portions of certain SAB topics.
The Company does not expect the adoption of ASU 2010-22 to have a material
impact on the Company’s financial position and results of
operations.
2. VARIABLE
INTEREST ENTITY
The
Company accounts for Variable Interest Entities (“VIE”) in accordance with ASC
810. As a result of the adoption of ASU 2009-17, consolidations (Topic 810) –
Improvements to Financial Reporting by Enterprises Involved with Variable
Interest Entities, effective January 1, 2010, ASC 810 requires the consolidation
of VIEs in which a company has both the power to direct the activities of the
VIE that most significantly impact the VIE’s economic performance and the
obligation to absorb losses or the right to receive the benefits from the VIE
that could potentially be significant to the VIE. The Company has applied the
requirements of ASC 810 on a prospective basis from the date of
adoption.
10
The
Company assesses all newly created entities and those with which the Company
becomes involved to determine whether such entities are VIEs and, if so, whether
or not the Company is their primary beneficiary.
On June
14, 2010, the Company through its PRC subsidiary, Shouzhi entered into a series
of contractual arrangements with GDH and the sole stockholder of GDH pursuant to
which Shouzhi assumed the management of the business activities of GDH and GDH
agreed to pay 100% of its profit to Shouzhi and Shouzhi agreed to absorb 100% of
the loss incurred by GDH. Through this arrangement, GDH is considered a VIE of
the Company.
As
required by ASC 810-10, the Company performs a qualitative assessment to
determine whether the Company is the primary beneficiary of GDH which is
identified as a VIE of the Company. A quality assessment begins with
an understanding of the nature of the risks in the entity as well as the nature
of the entity’s activities including terms of the contracts entered into by the
entity, ownership interests issued by the entity and the parties involved in the
design of the entity. The Company’s assessment on the involvement with GDH
reveals that the Company has the absolute power to direct the most significant
activities that impact the economic performance of GDH. Under the accounting
guidance, the Company is deemed to be the primary beneficiary of GDH and the
results of GDH are consolidated in the Company’s consolidated financial
statements for financial reporting purposes. As of September 30, 2010, GDH had
total assets of $9,179,332 and total liabilities of $4,774,831. As of December
31, 2009, GDH had total assets of $10,128,906 and total liabilities of
$5,761,397.
3. NOTE
PAYABLE
|
Note
payable at September 30, 2010 and December 31, 2009 consisted of the
following:
|
September
30,
|
December
31,
|
|||||||
2010
|
2009
|
|||||||
(Consolidated
and unaudited)
|
(Combined)
|
|||||||
Note
payable to a bank, interest rate of 6.34% per annum, collaterized by
buildings of the Company, guaranteed by a stockholder of the
Company and his spouse, due December 2014
|
$ | - | $ | 731,294 |
On June 12, 2010, the note payable was
fully repaid and therefore, the note payable is wholly classified as a current
liability as of December 31, 2009.
Interest
expense paid for the three and nine months ended September 30, 2010 was $0 and
$20,122, respectively.
4. COMMITMENTS
AND CONTINGENCIES
(A) Lease
commitments
The
Company leases staff quarters from third parties under three operating leases
which expire on January 1, 2012, December 31, 2010 and December 31, 2010 at
annual rental of $6,345, $4,054, and $14,100 respectively.
As of
September 30, 2010, the Company has outstanding commitments with respect to the
above operating leases, which are due as follows:
11
2010
|
$ | 6,225 | ||
2011
|
6,450 | |||
$ | 12,675 |
(B)
|
Capital
commitments
|
As of
September 30, 2010, the Company had capital commitments of $247,384 with respect
to the purchase of medical equipment.
5. RELATED PARTY
TRANSACTIONS
As of
September 30, 2010, the Company owed a stockholder $2,922 for advances made
which is unsecured and repayable on demand. Imputed interest expense is computed
at 5% per annum on the amount due for the nine months ended September 30,
2010.
As of
September 30, 2010, the Company owed a stockholder $3,583,106 which is unsecured
and repayable within 5 years commencing from January 1, 2011. Amount of $537,466
is repayable within one year and classified as current liabilities and the
remaining balance of $3,045,640 is classified as long-term liabilities. Interest
is charged at 5% per annum and amounted to $44,302, $40,054, $132,035 and
$127,561 for the three and nine months ended September 30, 2010 and 2009
respectively.
As of
September 30, 2010, the Company owed a related company $205,756 for advances
made which is unsecured, interest-free and repayable on demand. Imputed interest
expense is computed at 5% per annum on the amount due for the nine months ended
September 30, 2010.
Imputed
interest expenses charged at 5% per annum on amounts owed to a stockholder
and a related company recorded as additional paid-in capital amounted to $864,
$2,391, $3,569 and $7,170 for the three and nine months ended September 30, 2010
and 2009 respectively.
6. CONCENTRATIONS
AND RISKS
During
2010 and 2009, 100% of the Company's assets were located in the PRC and Hong
Kong and 100% of the Company's revenues were derived from patients in the
PRC.
The
Company had primarily two suppliers of medicine for approximately $45,745 and
$25,708 representing in aggregate 45% of purchases made for the nine months
ended September 30, 2010. As of September 30, 2010, accounts payable to these
suppliers totaled $27,414.
The
Company had primarily five suppliers of medicine for approximately $59,130,
$37,737, $25,843, $24,580, and $23,841 representing in aggregate 69% of
purchases made for the nine months ended September 30, 2009. As of September 30,
2009, accounts payable to these suppliers totaled $88,725.
Item
2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations.
The
following discussion and analysis of our results of operations and financial
condition should be read together with our condensed consolidated financial
statements and the notes thereto included elsewhere in this quarterly
report.
Information
contained in this section and expressed in dollars has generally been presented
in round numbers. Percentages contained in this section have been
calculated, where possible, using the information from our condensed
consolidated financial statements, and not the rounded information provided in
this section. As a result, these percentages may differ slightly from
calculations obtained based upon the rounded figures provided in this section
and totals contained in this section may be affected by rounding.
12
Statements
included in this quarterly report that do not relate to present or historical
conditions are called “forward-looking statements.” Such
forward-looking statements involve known and unknown risks and uncertainties and
other factors that could cause actual results or outcomes to differ materially
from those expressed in, or implied by, the forward-looking
statements. Forward-looking statements may include, without
limitation, statements relating to our plans, strategies, objectives,
expectations and intentions. Words such as “believes,” “forecasts,”
“intends,” “possible,” “estimates,” “projects,” “anticipates,” “future,”
“expects,” “plans,” “goal,” “objective,” “should,” “could,” “will,” and similar
expressions are intended to identify forward-looking statements. We
have based these forward-looking statements largely on our current expectations
and projections about future events and trends that we believe may affect our
financial condition, results of operations, business strategy and financial
needs. These forward-looking statements include, but are not limited
to, the following:
|
·
|
statements contained in “Item
1A. Risk Factors” of Amendment No. 3 to our Registration
Statement on Form 10, as filed with the Securities and Exchange Commission
(the “SEC”) on November 10, 2010;
and
|
|
·
|
statements
contained in “Item 2. Management’s Discussion and Analysis of
Financial Condition and Results of Operations” and the notes to our
condensed consolidated financial statements, such as our ability to
control additional hospitals on favorable terms, potential changes in
governmental regulation of our business, and our critical accounting
policies and estimates.
|
Our
ability to predict or project future results or the effect of events on our
operating results is inherently uncertain. Forward-looking statements
should not be read as a guarantee of future performance or results, and will not
necessarily be accurate indications of the times at, or by which, such
performance or results will be achieved.
Important
factors, risks and uncertainties that could cause actual performance or results
to differ materially from those expressed in or implied by, forward-looking
statements include, but are not limited to:
|
·
|
our limited operating
history;
|
|
·
|
that we may not be able to obtain
sufficient financing or raise sufficient capital as needed or desired for
operations or to expand and grow our
business;
|
|
·
|
our management company may be
unable to provide services to and to collect the income from the hospitals
to which it provides
services;
|
|
·
|
the hospital we operate may be
unable to distribute cash to the management
company;
|
|
·
|
any adverse developments related
to our sole hospital located in Guangzhou, Guangdong Province, China or
the other hospitals we may control in the
future;
|
|
·
|
our inability to obtain the
necessary government registrations, approvals and licenses for our planned
acquisitions and hospital
expansions;
|
|
·
|
our inability to integrate and
manage the acquisition of new hospitals and the expansion of our
operations;
|
|
·
|
the uncertainties of the
interpretation and application of current and future PRC laws and
regulations, including regulations governing the validity and enforcement
of our contractual arrangements we use and plan to use to operate our
hospital;
|
|
·
|
our loss of ability to use and
enjoy assets of the management company or the hospital in the event of
their respective
bankruptcies;
|
|
·
|
overall regulations and laws in
China, including without limitation those in the healthcare industry, and
any changes in those laws, rules or regulations, which may adversely
affect our ability to operate profitably or at
all;
|
13
|
·
|
the negative effects of increased
competition in the private hospital sector in China, including the impact
that such competition may have on our ability to locate and obtain control
over the operations of other hospitals in
China;
|
|
·
|
our inability to remain eligible
for the payment of medical fees through insurance coverage under the laws
of the PRC and its provinces and
municipalities;
|
|
·
|
that we may be unable to continue
to attract, hire, retain, promote and compensate physicians and other
healthcare professionals as we need to or deem appropriate in connection
with the proposed expansion of our
business;
|
|
·
|
our inability to retain our key
senior management, including Xu Jianping, our Chairman, President and
Chief Executive Officer;
|
|
·
|
our inability to successfully
centralize operations to take advantage of cost savings and other
economies of scale that may be enjoyed by a larger operator of
hospitals;
|
|
·
|
our lack of general and
professional liability insurance, including healthcare malpractice
insurance, which subjects us to potential exposure to malpractice,
liability and other claims;
|
|
·
|
our inability to maintain
effective disclosure or internal
controls;
|
|
·
|
general changes in economic and
business conditions in China and in the regions in which we operate;
and
|
|
·
|
other factors described under
“Item 1A. Risk Factors” in our Form 10 registration
statement.
|
Overview
and Strategy
We
currently operate GDH, a general hospital located in Guangzhou, Guangdong
Province, China. Our management has operated GDH since 2002, and we
indirectly acquired the contractual right to operate GDH in June
2010. GDH currently has 90 licensed beds and offers a wide range of
medical services in the areas of surgery, internal medicine, ophthalmology,
orthopedics, oncology, cardiovascular disease, urology, dentistry, gynecology,
tocology, pediatrics, traditional Chinese medicine, rehabilitation and emergency
care. We intend to focus our healthcare services at GDH
primarily in the areas of gynecology, obstetrics and oncology, emphasizing high
quality patient care and medical services by offering advanced technology and
equipment in a setting staffed by doctors, nurses and other medical
professionals who seek to provide the highest level of healthcare for
patients.
We seek
to operate high-quality hospitals throughout China to focus on providing
specialized medical services to patients, particularly in the medical
specialties of oncology, cardiovascular disease, gynecology, obstetrics and
minimally invasive surgery. During the next 12 to 18 months, we
intend to acquire operational control of two or three small and medium-sized
hospitals located in Guangdong, Hunan, Jiangxi or other provinces in
China. We are targeting hospitals with less than 1,000 licensed beds
and less than RMB 100 million of annual revenue. Our long-term goal
is to acquire operational control of up to 10 hospitals or more during the next
three years.
We were
formed as a Nevada corporation on September 29, 2009 to acquire operational
control over GDH. Due to restrictions on the foreign ownership of
medical facilities in China, we operate our business through ownership of the
management company that provides management, consulting, investment and
technical services to GDH. We do not own any direct equity interest
in GDH.
14
On June
14, 2010, GDH entered into a series of contractual arrangements with Guangzhou
Shouozhi Medical Institution Management Co. Ltd., or the management company, and
Xu Jianping, the sole shareholder of GDH. The management company was
formed as a limited liability company and a wholly foreign-owned enterprise
under the laws of the PRC on November 13, 2009. The management
company was formed to acquire the right to operate and control hospitals located
in China, and, when and as permitted under PRC law, the right to own
them. The management company received its business license on
November 13, 2009 from the Guangzhou Municipal Administration for Industry and
Commerce. Mr. Xu is also our President and Chief Executive Officer
and the beneficial owner of approximately 54% of our common
stock. These contractual arrangements effectively give the management
company operational control over GDH despite the lack of direct
ownership. As a result of these contractual arrangements, we treat
GDH as a variable interest entity, or VIE, under U.S. generally accepted
accounting principles, and we have included its historical financial results in
our condensed consolidated financial statements. A summary of these
agreements is provided below.
Exclusive Management Consultancy
Agreement. GDH and Mr. Xu have agreed to engage the management
company as the exclusive management consultant under the terms of this
agreement. GDH and Mr. Xu have granted to the management company full
and exclusive responsibility for the operation and management of GDH, including,
without limitation, the right to:
|
·
|
appoint, oversee and remove its
management, supervisory and administrative
personnel;
|
|
·
|
fully control and administer the
internal financial affairs and daily operations of GDH, including the
execution and performance of all contracts and the payment of
taxes;
|
|
·
|
control all working capital,
income and other funds of GDH;
and
|
|
·
|
control all other decisions
related to the operations of
GDH.
|
In
exchange for providing these management services, GDH will pay the management
company a monthly management consultancy fee equal to the net profits of GDH,
which is defined to mean all its revenues, less its operating costs, expenses
and taxes. Unless the parties mutually agree to terminate the
exclusive management agreement, GDH will continue to be managed by the
management company until the earlier of:
|
·
|
the date on which the business
term of GDH expires and is not renewed within the applicable period of
time provided under applicable law for such
renewal;
|
|
·
|
the acquisition by the management
company of all of the equity interests in GDH;
or
|
|
·
|
the occurrence of a force majeure
event, as defined under the exclusive management
agreement.
|
No
management fee is received if GDH does not generate a profit. Also,
even if GDH generates a profit, GDH may nevertheless be unable to pay the
management fee if it does not have sufficient disposable cash on
hand. For example, GDH may record a profit from non-cash items but
there could be insufficient funds to pay the fee in whole or in part, or the
management company and GDH may determine that the profit should be retained by
GDH for operations. As of September 30, 2010, the amount of
management fees paid by GDH to the management company since inception of the
Exclusive Management Consultancy Agreement was $92,499.
Call Option
Agreement. The management company, GDH and Mr. Xu have entered
into a call option agreement whereby Mr. Xu has granted to the management
company (or its designee) an option to purchase all or any part of the equity
interests held by Mr. Xu in GDH to the extent permitted by PRC
law. The purchase price for the equity in GDH would be equal to the
original investment paid by Mr. Xu, unless applicable PRC law would require
appraisal of the equity interests or impose other restrictions on the purchase
price, in which case the purchase price will be set at the lowest price
permissible under applicable law. Also, GDH has granted, with Mr.
Xu’s approval, the management company (or its designee) an option to purchase
all or part of its assets to the extent permitted by PRC law. The
purchase price for the assets of GDH will be negotiated by the parties, or, if
an appraisal or other restrictions on the purchase price are required under PRC
law, the price will be the lowest price permitted by PRC law. In
addition to the limitations on foreign ownership of healthcare institutions in
the PRC, PRC regulations currently in effect prohibit an exercise price for such
option which is lower than the appraised fair value of the business or assets
being acquired.
15
Shareholders’ Voting Proxy
Agreement. Under this agreement, Mr. Xu has irrevocably
entrusted the management company to exclusively exercise Mr. Xu’s voting rights
as the sole shareholder of GDH, and Mr. Xu has given the management company an
irrevocable proxy with respect to all of the shares of GDH he current owns or
may acquire in the future. Prior to the acquisition of GDH by the
management company, this agreement may be terminated upon the mutual
consent of the parties to such agreement or with the consent of the management
company upon 30 days written notice to Mr. Xu.
Share Pledge
Agreement. Under this agreement, Mr. Xu pledged all of his
equity interests in GDH to the management company to guarantee the performance
of all obligations of Mr. Xu and GDH under the foregoing
agreements. In the event of default, including any failure to perform
their obligations under any of these agreements, unless Mr. Xu and GDH correct
the default to the management company’s satisfaction, the management company may
seek to foreclose on the pledged equity. Presently, however, the
management company’s ability to directly own the equity of GDH is subject to
significant PRC governmental regulation, including governmental approvals that
would be required before such equity could be legally transferred to the
management company.
GDH
derives revenue primarily from two types of patient services: patient
revenue, which is comprised mainly of inpatient admissions and outpatient
medical services, as well as the sale of medicine. Charges and fees
for medical services may vary significantly depending on the type of service
provided. In the future, as we acquire control of additional
hospitals, we expect that our medical services revenue will vary by the
geographic location of the hospital.
During
2009, GDH entered into two cooperation agreements designed to internally grow
GDH’s operations. First, in June 2009, GDH entered into an eight-year
exclusive cooperation agreement with Yang Wei, a licensed dentist, to jointly
organize and operate a dental clinic to be housed at GDH, which services are not
currently offered by GDH. This clinic provides patients with a
variety of dental services and medicines. GDH is responsible for
providing dental chairs, treatment units and other equipment, as well as the
medical staff. The parties have agreed to split revenues from the
dental center, and Mr. Yang has agreed to provide us with a minimum amount of
revenue each month. The dental clinic has been operational since June
1, 2009. Our revenue derived from the dental center with Yang Wei was
$26,109, or approximately 0.6%, for the year ended December 31, 2009, and
$13,460 and $38,335, or approximately 1.2% and 1.2%, for the three and nine
months ended September 30, 2010 respectively.
Second,
GDH entered into a five-year cooperation agreement in September 2009 with Luo
Quanhong to invest in the Guangdong Province Medical Association Medical
Center. Mr. Luo is a licensed physician specializing in
surgery. The cooperation agreement requires us to provide a facility,
equipment and operating permit to be able to treat patients in this medical
center. Mr. Luo is responsible for paying utilities, taxes and
security for the medical center, and provided an initial investment of RMB
200,000. Other expenses are to be allocated to the medical center.
The parties have agreed to split revenues from the medical center depending on
its source and Mr. Luo has agreed to provide us with a minimum amount of revenue
each year. The medical center has been operational since September 8,
2009. Our revenue derived from the medical center with Luo Quanhong was
$29,896, or approximately 0.7%, for the year ended December 31, 2009, and $7,941
and $46,363, or approximately 0.7% and 1.5%, for the three and nine months ended
September 30, 2010, respectively.
Critical
Accounting Policies and Estimates
In
preparing our condensed consolidated financial statements in conformity with
accounting principles generally accepted in the United States, we make estimates
and assumptions that affect the accounting, recognition and disclosure of our
assets, liabilities, stockholders’ equity, revenues and expenses. We
make these estimates and assumptions because certain information that we use is
dependent upon future events, cannot be calculated with a high degree of
precision from data available or cannot be readily calculated based upon
generally accepted methodologies. In some cases, these estimates are
particularly difficult and therefore require a significant amount of
judgment. Actual results could differ from the estimates and
assumptions that we use in the preparation of our condensed consolidated
financial statements.
Except as
noted below, there have not been any significant changes to our critical
accounting policies discussed under “Item 2. Financial Information —
Management’s Discussion and Analysis of Financial Condition and Results of
Operations – Critical Accounting Policies and Estimates” included in our Form 10
registration statement.
16
Accounts Receivable and Allowance
for Doubtful Accounts. Substantially all of our receivables
are related to providing healthcare services to hospital patients with insurance
coverage. With respect to patients covered by governmental programs
and private insurers, the amounts we receive for treating such patients is
generally less than our established billing rates. Accordingly, we
record our accounts receivable at the net amount expected to be received and we
require the patient to pay the difference between the gross charge and such
expected reimbursable amount in cash at the time of service. Our
standard collection procedures are then followed until such time that management
may determine the account to be uncollectible, at which point the account would
be written off. As of September 30, 2010 and December 31, 2009 and
2008, however, we considered all of our accounts receivable to be collectible
and no provision for doubtful accounts has been made in our combined and
condensed consolidated financial statements.
We
continually monitor our accounts receivable balances and utilize cash
collections data and other analytical tools to determine whether a provision for
doubtful accounts should be made. Should any provision for doubtful
accounts be established, we would perform procedures on historical collections
and write-off experience to determine the reasonableness of estimations of the
allowance for doubtful accounts. The amount of this allowance would
reflect changes in payer mix or business office operations, or deterioration in
aging accounts receivable. Our policy with respect to estimating the
allowance for doubtful accounts for uninsured receivables is entirely within
management’s discretion and there is no general and specific rule for its
calculation. However, based on our past experience, the
collectability of uninsured receivables that are aged over nine months would be
remote, and a provision for the full amount of the receivable would then
generally be taken. If the management has credible evidence that the
receivables will not be collected, the provision is written off against trade
receivables.
The
following table provides an aging analysis for our accounts receivable as of
September 30, 2010 and December 31, 2009.
Aging
Analysis
|
||||||||||||||||||||||||||||||||
As
of
|
Ending
Balance
|
0-30
Days
|
30-90
Days
|
90-180
Days
|
180-365
Days
|
1-2
Years
|
2
Years
or
Above
|
Opening
Balance
|
||||||||||||||||||||||||
September
30, 2010
|
$ | 160,299 | $ | 24,945 | $ | 125,222 | $ | 10,024 | $ | 108 | $ | - | $ | - | $ | 100,909 | ||||||||||||||||
December
31, 2009
|
$ | 100,909 | $ | 18,400 | $ | 81,316 | $ | 1,136 | $ | 57 | $ | - | $ | - | $ | 85,035 |
The
following table sets forth the payor mix concentrations of our accounts
receivable as of September 30, 2010 and December 31, 2009,
respectively.
Accounts
Receivable Due
from
Medicare Patients
|
Accounts
Receivable
Due
from Self-Pay Patients
|
Accounts
Receivable Due From
Private
Insurers
|
||||||||||||||||||||||
As
of
|
$ |
%
of Total
Receivables
|
$ |
%
of Total
Receivables
|
$ |
%
of Total
Receivables
|
||||||||||||||||||
September
30, 2010
|
$ | 134,651 | 84.0 | % | — | — | % | $ | 25,648 | 16.0 | % | |||||||||||||
December
31, 2009
|
$ | 83,516 | 82.8 | % | — | — | % | $ | 17,393 | 17.2 | % |
The
following table discloses the differences between the expected amounts to be
received from or on behalf of Medicare patients (both from the patient and from
Medicare) and the amounts actually received, for each of the nine months ended
September 30, 2010 and the year ended December 31, 2009.
17
For
the Nine
Months
Ended
September
30,
2010
|
For
the Year
Ended
December
31,
2009
|
|||||||
Total
revenue from Medicare patients
|
$ | 223,890 | $ | 218,338 | ||||
Revenue
associated with Medicare payment
|
$ | 156,030 | $ | 147,961 | ||||
Total
amounts paid by Medicare
|
$ | 104,921 | $ | 140,153 | ||||
Total
due from Medicare
|
$ | 134,625 | $ | 83,516 | ||||
Total
revenue from self-pay patients
|
$ | 67,860 | $ | 70,377 | ||||
Total
amounts received from self-pay patients
|
$ | 67,860 | $ | 70,377 | ||||
Total
due from individuals
|
$ | — | $ | — |
We expect
that revenue derived from patients covered by Medicare will continue to increase
as a percentage of overall revenue, and, as a result, the amount of our accounts
receivable attributable to such Medicare patients will
increase. Beginning in fiscal year 2011, we anticipate that we will
need to establish a provision for doubtful accounts as our total amount of
accounts receivable increases.
The
following table presents our credit sales, total average accounts receivable and
days sales outstanding for the year ended December 31, 2009, and for the nine
months ended September 30, 2010.
Year
Ended
December
31, 2009
|
Nine
Months Ended
September
30, 2010
|
|||||||
Credit
sales
|
$ | 221,861 | $ | 249,538 | ||||
Total
average accounts receivable
|
$ | 92,972 | $ | 130,605 | ||||
Period
(days)
|
360 | 270 | ||||||
Days
sales outstanding
|
151 | 141 |
Our days
sales outstanding, or DSO, was 141 days and 151 days for the nine months ended
September 30, 2010 and for the year ended December 31, 2009. The DSO
decreased by 10 days for the nine months ended September 30, 2010 as compared to
the year ended December 31, 2009.
The
decrease of 10 days for the nine months ended September 30, 2010 compared to the
year ended December 31, 2009 was recognized together with an increase of $37,633
in total average accounts receivable and an increase of $27,677 in credit sales.
The increase in total average accounts receivable was attributable to an
increase of $51,136 in accounts receivable due from Medicare which was
attributable to an increase of $85,927 in total revenue from Medicare patients
for the nine months ended September 30, 2010 compared to the six months ended
June 30, 2010.
Results
of Operations – Three Months Ended September 30, 2010 Compared to Three Months
Ended September 30, 2009
The
following table presents, for the periods indicated, a summary of selected
consolidated unaudited statement of operations information for the three months
ended September 30, 2010 and September 30, 2009. Our third quarter of
2010 results may not be indicative of our full year results for our fiscal year
ending December 31, 2010 or future quarterly periods.
18
For
the Three Months Ended
September
30
|
||||||||
2010
|
2009
|
|||||||
(Unaudited)
|
(Unaudited)
|
|||||||
Patient
Service Revenue:
|
||||||||
Patient
revenue
|
$ | 799,086 | $ | 912,330 | ||||
Sale
of medicine
|
290,005 | 300,051 | ||||||
Total
Patient Service Revenue
|
1,089,091 | 1,212,381 | ||||||
Cost
of Revenue:
|
||||||||
Cost
of patient revenue
|
355,522 | 474,248 | ||||||
Cost
of medicine
|
149,928 | 66,209 | ||||||
Depreciation
|
145,273 | 142,284 | ||||||
Total
Cost of Revenue
|
650,723 | 682,741 | ||||||
Gross
Profit
|
438,368 | 529,640 | ||||||
Operating
Expenses:
|
||||||||
Selling,
general and administrative expenses
|
218,094 | 170,042 | ||||||
Professional
fees
|
35,313 | - | ||||||
Amortization
of land use rights
|
10,294 | 10,203 | ||||||
Depreciation
|
88,542 | 90,140 | ||||||
Total
Operating Expenses
|
352,243 | 270,385 | ||||||
Income
from Operations
|
86,125 | 259,255 | ||||||
Other
Expense, net
|
(44,165 | ) | (42,445 | ) | ||||
Net
Income Before Taxes
|
41,960 | 216,810 | ||||||
Income
Tax Expense
|
— | — | ||||||
Net
Income
|
$ | 41,960 | $ | 216,810 | ||||
Net
Income Per Share (Basic and Diluted)
|
$ | 0.00 | $ | 0.01 | ||||
Weighted
Average Shares of Common Stock Outstanding During the Period (Basic and
Diluted)
|
21,000,000 | 21,000,000 | ||||||
Other
Comprehensive Income – Foreign Currency Translation Gains
|
$ | 84,895 | $ | 4,299 | ||||
Comprehensive
Income
|
$ | 126,855 | $ | 221,109 |
Patient
Service Revenue
During the three months ended
September 30, 2010, we had total patient service revenue in the amount of
$1,089,091. Of this, $799,086 was attributable to revenue generated
from our medical services, and $290,005 was attributable to our sales of
medicine. During the three months ended September 30, 2009, we had total
operating revenue in the amount of $1,212,381. Of this, $912,330 was
attributable to revenue generated from our medical services, and $300,051 was
attributable to our sales of medicine. The decrease in our patient
service revenue during the three months ended September 30, 2009 to the three
months ended September 30, 2010 was $123,290, or approximately 10%. The decrease
in revenue was the result of the reduction of tumor patients, which was
attributable to the reduction in marketing and promotion and the maintenance of
tumor treatment equipment in the third quarter. We have noticed this
result and will adjust our next marketing and promotion projects; as a result,
we expect there may be an increase in revenue from tumor patients in the
future.
Cost
of revenue
Cost of
revenue is comprised of cost of patient revenue, cost of medicine and
depreciation. Cost of patient revenue is comprised of salaries,
health materials, business expenses, promotion and training expenses, repairs
and maintenance, cooperating expenses, motor vehicle expenses, travel expenses,
consumables and other miscellaneous expenses.
19
Cost of
revenue for the three months ended September 30, 2010 was $650,723, as compared
to $682,741 for the three months ended September 30, 2009, a decrease of
$32,018, or approximately 5%. The decrease in cost of revenue was primarily
attributable to lower costs of patient revenue, which decreased by $118,726, or
approximately 25%, and higher costs of medicine, which increased by $83,719, or
approximately 126%. The decrease in the cost of patient revenue was primarily
attributed to a decrease of $121,302 in promotion and marketing expenses. In the
third quarter of 2010, in order to reduce the expenses of promotion and
marketing, we did our promotion and marketing primarily by a free consultant,
which is a lower cost. Every Saturday, we sent our doctors to
surrounding communities to provide free medical consultations and checkups for
residents. The increase of $83,719 in the cost of medicine was
primarily attributable to the activities on medicine bargains in the third
quarter of 2010. During the third quarter of 2010, we reduced all of
the common medicine prices by 30% to attract patients, and this directly led to
an increase in cost of medicine and a decrease in revenue from medicine
sales.
Depreciation
increased by approximately $2,989, which was attributed to an increase of
$66,761 in medical equipment during the nine months ended September 30, 2010
compared to 2009. Depreciation included in cost of revenue is with respect to
medical equipment which is used directly for production or operation of
revenue.
Gross
profit
Gross
profit was reduced from $529,640 for the three months ended September 30, 2009
to $438,368 for the three months ended September 30, 2010, a decrease of
$91,272, or 17%, which was largely attributable to the decrease of $123,290 in
the patient service revenue and the decrease of $32,018 in the cost of
revenue. Gross margins for the three months ended September 30, 2009
and 2010 were 44% and 40% respectively. While management believes
that these gross margins are typical results, we seek to maintain them in the
future to over 40% by increasing our revenue and decreasing our costs and
adjusting our revenue mix to more profitable, higher margin procedures and
medical services.
Operating
expenses
Operating
expenses for the three months ended September 30, 2010 were $352,243, as
compared to $270,385 for the three months ended September 30, 2009, an increase
of $81,858, or approximately 30%. Operating expenses are comprised of
selling, general and administrative expenses, professional fees, amortization of
land use rights and depreciation on fixed assets which are not used directly for
production and operations.
The
increase in operating expenses was primarily attributable to an increase of
$35,313 in professional, consulting and audit fees incurred in connection with
our seeking to be a public reporting company in the United States and the
preparation of our registration statement on Form 10, and an increase of $48,052
in general business expenses incurred in connection with our seeking to acquire
control of a new hospital.
Other
expense, net
Other
expense, net for the three months ended September 30, 2010 was $44,165, as
compared to $42,445 for the three months ended September 30, 2009, an increase
of $1,720 or 4%, which was primarily attributable to an increase of $4,248 in
interest expense to a stockholder, offset by an increase of $1,001 in interest
income, a decrease of $1,527 in imputed interest.
Income
tax expense
Although
there was net income of $41,960 for the three months ended September 30, 2010,
as a result of our net loss for the nine months
ended September 30, 2010, according to PRC income tax law, current profit should
first be used to cover previous losses, so we did not incur any income tax
expense for the three months ended September 30, 2010. We did not
incur income tax expense during the three months ended September 30, 2009 as we
were a not-for-profit entity during such period. We expect our
overall effective income tax rate will be approximately 25% in 2010, as GDH will
be a for-profit entity for all of 2010.
Net
income
Net
income for the three months ended September 30, 2010 was $41,960, as compared to
$216,810 for the three months ended September 30, 2009, a decrease of $174,850,
or 81%. The decrease in net income was primarily attributable to a
decrease of $123,290 in patient service revenue and an increase of operating
expenses by $81,858 from period to period, and a decrease cost of revenue by
$32,018 for the three months ended September 30, 2010 as compared to the year
prior period.
20
Other
comprehensive income
Other
comprehensive income for the three months ended September 30, 2010 and 2009
reflects foreign currency translation gains and was $84,895 and $4,299,
respectively. The increase in foreign currency translation gains from
period to period was primarily caused by a change in the RMB to U.S. dollar
exchange rate in 2010 compared to 2009.
Results
of Operations — Nine Months Ended September 30, 2010 Compared to Nine Months
Ended September 30, 2009
The
following table presents, for the periods indicated, a summary of selected
consolidated unaudited statement of operations information for the nine months
ended September 30, 2010 and September 30, 2009. Our third quarter of
2010 results may not be indicative of our full year results for our fiscal year
ending December 31, 2010 or future quarterly periods.
For
the Nine Months Ended
September
30
|
||||||||
2010
|
2009
|
|||||||
(Unaudited)
|
(Unaudited)
|
|||||||
Patient
Service Revenue:
|
||||||||
Patient
revenue
|
$ | 2,320,705 | $ | 2,269,138 | ||||
Sale
of medicine
|
772,174 | 762,752 | ||||||
Total
Patient Service Revenue
|
3,092,879 | 3,031,890 | ||||||
Cost
of Revenue:
|
||||||||
Cost
of patient revenue
|
1,263,124 | 1,147,854 | ||||||
Cost
of medicine
|
311,205 | 234,772 | ||||||
Depreciation
|
431,156 | 424,142 | ||||||
Total
Cost of Revenue
|
2,005,485 | 1,806,768 | ||||||
Gross
Profit
|
1,087,394 | 1,225,122 | ||||||
Operating
Expenses:
|
||||||||
Selling,
general and administrative expenses
|
606,696 | 531,223 | ||||||
Professional
fees
|
74,138 | 1,169 | ||||||
Amortization
of land use rights
|
30,719 | 30,602 | ||||||
Depreciation
|
279,024 | 270,157 | ||||||
Total
Operating Expenses
|
990,577 | 833,151 | ||||||
Income
from Operations
|
96,817 | 391,971 | ||||||
Other
Expense, net
|
(148,874 | ) | (134,731 | ) | ||||
Net
Income (Loss) Before Taxes
|
(52,057 | ) | 257,240 | |||||
Income
Tax Expense
|
— | — | ||||||
Net
Income (Loss)
|
$ | (52,057 | ) | $ | 257,240 | |||
Net
Income (Loss) Per Share (Basic and Diluted)
|
$ | (0.00 | ) | $ | 0.01 | |||
Weighted
Average Shares of Common Stock Outstanding During the Period (Basic and
Diluted)
|
21,000,000 | 21,000,000 | ||||||
Other
Comprehensive Income – Foreign Currency Translation Gains
|
$ | 102,937 | $ | 9,899 | ||||
Comprehensive
Income
|
$ | 50,880 | $ | 267,139 |
Patient
service revenue
During the nine months ended
September 30, 2010, we had total patient service revenue in the amount of
$3,092,879. Of this, $2,320,705 was attributable to revenue generated from our
medical services, and $772,174 was attributable to our sales of medicine. During
the nine months ended September 30, 2009, we had total operating revenue in the
amount of $3,031,890. Of this, $2,269,138 was attributable to revenue
generated from our medical services, and $762,752 was attributable to our sales
of medicine. The increase in our patient service revenue during the
nine months ended September 30, 2009 to the nine months ended September 30, 2010
was $60,989, or approximately 2%. The increase in revenue was the result of more
patients being treated by our hospital and our publicity and promotional efforts
in the first quarter of 2010.
21
Cost
of revenue
Cost of
revenue is comprised of cost of patient revenue, cost of medicine and
depreciation. Cost of patient revenue is comprised of salaries,
health materials, business expenses, promotion and training expenses, repairs
and maintenance, cooperating expenses, motor vehicle expenses, travel expenses,
consumables and other miscellaneous expenses.
Cost of
revenue for the nine months ended September 30, 2010 was $2,005,485, as compared
to $1,806,768 for the nine months ended September 30, 2009, an increase of
$198,717, or approximately 11%. The increase in cost of revenue was primarily
attributable to an increase of $115,270 in cost of patient revenue and an
increase of 76,433 in cost of medicine. The increase of 115,270 in cost of
patient revenue was primarily attributable to an increase of $55,312 in training
expenses and an increase of $70,387 in promotion and marketing expenses. For the
future development of our business, we increased investment in training,
promotion and marketing during the nine months ended September 30, 2010. We
believe that those increased costs would be helpful for improving our future
business. The increase of $76,433 in the cost of medicine was
primarily attributable to our offering reduced prices for all common medicine by
more than 30% during the third quarter of 2010 to attract new
patients. This directly led to an increase in cost of medicine and a
decrease in revenue from medicine sales.
Depreciation
increased by approximately $7,014, which was attributed to an increase of
$95,060 in medical equipment from the third quarter of 2009 as compared to the
third quarter of 2010. Depreciation included in cost of revenue is
with respect to medical equipment which is used directly for production or
operation of revenue.
Gross
profit
Gross
profit was reduced from $1,225,122 for the nine months ended September 30, 2009
to $1,087,394 for the nine months ended September 30, 2010, a decrease of
$137,728, or 11%, which was largely attributable to the increase of $198,717 in
cost of revenue. Gross margins for the nine months ended September
30, 2009 and 2010 were 40% and 35% respectively. While management
considers the gross margins of 35% in the third quarter of 2010 was lower than
their expectation, we seek to improve them in the future to over 40% by
increasing our revenue and decreasing our costs and adjusting our revenue mix to
more profitable, higher margin procedures and medical services.
Operating
expenses
Operating
expenses for the nine months ended September 30, 2010 was $990,577, as compared
to $833,151 for the nine months ended September 30, 2009, an increase of
$157,426, or approximately 19%. Operating expenses are comprised of
selling, general and administrative expenses, professional fees, amortization of
land use rights and depreciation on fixed assets which are not used directly for
production and operations.
The
increase in operating expenses was primarily attributable to an increase of
$75,473 in selling, general and administrative expenses which was attributable
to an increase of $70,547 in business entertainment and business trip as we had
engaged in business activities to control new hospital operations, and an
increase of $72,969 in professional, consulting and audit fees in connection
with our seeking to be a public reporting company in the United States and our
preparation of our registration statement on Form 10.
Depreciation
increased by approximately $8,867, which was attributed to an increase of
$40,120 in office equipment during the nine months ended September 30, 2010 as
compared to 2009. Depreciation included in operating expenses is
attributable to equipment which is not used directly for production or operation
of revenue.
22
Other
expense, net
Other
expense, net for the nine months ended September 30, 2010 was $148,874, as
compared to $134,731 for the nine months ended September 30, 2009, an increase
of $14,143, or 10%, which was primarily attributable to an increase of $20,122
in our interest expense incurred on our notes payable, offset by an increase of
$6,852 in interest income.
Income
tax expense
As a
result of our net loss in the nine months ended September 30, 2010, we did not
incur any income tax expense. We did not incur income tax expense
during the nine months ended September 30, 2009 as we were a not-for-profit
entity during such period. We expect our overall effective income tax
rate will be approximately 25% in 2010, as GDH will be a for-profit entity for
all of 2010.
Net
loss
Net loss
for the nine months ended September 30, 2010 was $52,057, as compared to net
income of $257,240 for the nine months ended September 30, 2009. This
change was primarily attributable to an increase of operating expenses by
$157,426 from period to period, a decrease in gross profit by $137,728 in the
third quarter of 2010 as compared to the year prior period, and an
increase in other expense, net by $14,143 from period to period.
Other
comprehensive income
Other
comprehensive income for the nine months ended September 30, 2010 and 2009
reflects foreign currency translation gains and was $102,937 and $9,899,
respectively. The increase in foreign currency translation gains was
primarily caused by a change in the RMB to U.S. dollar exchange rate in 2010
compared to 2009.
Liquidity
and Capital Resources
Cash
and cash equivalents
Cash and
cash equivalents consist primarily of cash on hand and demand deposits at a
bank. We had $1,250,402 and $1,420,407 of cash and cash equivalents
on hand at September 30, 2010 and December 31, 2009,
respectively. There was a decrease of $170,005 in our cash and cash
equivalents from December 31, 2009 to September 30, 2010, which was largely
attributable to our repayment of in the aggregate approximately $1 million of a
note payable and amounts due to a stockholder, as well as approximately $0.1
million of cash paid to purchase certain equipment, offset by approximately $0.5
million in cash flow from operations and approximately $0.4 million in proceeds
from the issuance of Winmark common stock prior to our reorganization (see Note
1(B) to our Notes to Consolidated Financial Statements set forth in Part I, Item
1. Financial Statements above).
We
require cash for working capital, capital expenditures, repayment of debt,
salaries, commissions and related benefits and other operating expenses and
income taxes. We expect that our working capital needs will increase
for the foreseeable future, as we continue to develop and grow our
business.
Machinery
and medical equipment
In 2009,
we purchased approximately $0.2 million in property and equipment, primarily for
patient examination and treatment. Future payments for already
acquired medical equipment in 2010 are expected to be $0.1 million, and we
anticipate that we will need to spend approximately $0.4 million on new medical
equipment.
Summary
of cash flows
The
following table summarizes our cash flows for the nine months ended September
30, 2010 and 2009:
23
For
the Nine Months Ended
September
30,
|
||||||||
(unaudited)
(in thousands)
|
2010
|
2009
|
||||||
Net
cash provided by operating activities
|
$ | 542 | $ | 382 | ||||
Net
cash used in investing activities
|
$ | (135 | ) | $ | (168 | ) | ||
Net
cash used in financing activities
|
$ | (522 | ) | $ | (139 | ) |
Net Cash Provided By Operating
Activities. Our operating activities provided cash of $542,489
and $381,901 in the nine months ended September 30, 2010 and September 30, 2009,
respectively.
The most
significant items affecting the comparison of our operating cash flows for the
nine months ended September 30, 2010 and 2009 are summarized below:
|
·
|
Decrease in net income from
operations – Our net income from operations, excluding depreciation
and amortization, decreased by approximately $0.3 million on a
period-to-period basis. The decrease in net income from
operations was primarily attributed to our gross profit, which decreased
by approximately $140,000, and our operating expenses, which increased by
approximately $160,000 on a period-to-period basis. The
decrease in gross profit was primarily attributed to an increase of
$55,321 in training expenses and $70,387 in promotion and marketing
expenses, which we expended to support the future development of GDH, as
well as an increase of $76,433 in the cost of medicine, which was
attributable to our offering a discount on the cost of common
medicines. The increase of approximately $160,000 in operating
expenses was primarily attributable to an increase of $75,448 in selling,
general and administrative expenses, resulting from increased business
entertainment and travel expenses to seek new hospital operations, and an
increase of $72,969 in professional, consulting and audit fees in
connection with our seeking to be a public reporting company in the United
States and the preparation of our registration statement on Form
10. We believe that these increased costs will be helpful for
improving our future business.
|
|
·
|
Reduced increase in prepaid
expenses, other current assets and accounts receivable – Prepaid
expenses and other current assets increased by $97,895 in the third
quarter of 2010, while they increased by $27,704 in the third quarter of
2009. The accounts receivable increased by $59,390 and $201,290
in the third quarter of 2010 and 2009, respectively. The increase in
prepaid expenses in the third quarter of 2010 was primarily attributed to
an increase in purchases of medical instruments and medicine, compared
with the third quarter of 2009.The reduction in the increase in the
accounts receivable was primarily attributable to our strengthening of
control in accounts receivable.
|
|
·
|
Increase in
changes in accounts payable – Accounts payable increased by
$27,205 during the nine months ended September 30, 2010, while they
decreased by $118,958 during the nine months ended September 30,
2009. The period-to-period increase in change in accounts
payable was largely attributed to a $34,022 increase in amounts due to our
medicine providers.
|
|
·
|
Changes in
other payables and accrued expenses – Other payables and accrued
expenses decreased by $5,342 during the nine months ended September 30,
2010, while they decreased by $252,018 during the nine months ended
September 30, 2009. The difference was primarily attributable
to advances from customers, which decreased by $43,210, and the accrued
expenses for professional fees, which increased by
$38,933.
|
To enable
us to generate greater amounts of cash flows from our operations in the
long-term, we are planning to continue the following activities:
|
·
|
employ physicians and other
healthcare providers in specialties that we believe will improve
profitability;
|
24
|
·
|
employ new medical
technologies;
|
|
·
|
continue to train personnel to
improve medical services;
|
|
·
|
continue our marketing and
promotion campaigns, to improve public awareness of the hospital;
and
|
|
·
|
where it is possible and
feasible, establish competitive pricing for our
services.
|
Net
Cash Used in Investing Activities
Our
investing activities for the nine months ended September 30, 2010 and 2009 used
cash of $135,181 and $167,781, respectively. This improvement in cash
used by investing activities was largely caused by a decrease of $32,600 in the
amount of medical equipment and office equipment we purchased during the nine
months ended September 30, 2010.
Currently,
the main driver that affects our cash flow from investing activities is medical
equipment purchases. Through the end of 2010, we do not intend to
purchase more than $10,000 of new equipment; however, we do have $0.2 million in
equipment purchase payments due this year, and we will also need to spend $0.5
million on upgrades to our surgical equipment in 2010. We believe
that upgrading our medical equipment is necessary, and these purchases may
negatively impact our cash flow in the future when they are made.
Net
Cash Used in Financing Activities
The most
significant items affecting the comparison of our cash flows used in financing
activities for the nine months ending September 30, 2010 and 2009 are summarized
below:
|
·
|
Proceeds from issuance of
Winmark common stock. Our proceeds from issuance of
common stock for the nine months ended September 30, 2010 and 2009 was
$466,709 and $43,829, respectively. On April 1, 2010, Winmark issued 2,830
shares of common stock to a company controlled by certain employees of GDH
at a premium of $203 per share. As of June 30, 2010, the stock
subscription of $466,709 was fully
received.
|
|
·
|
Repayment of existing amounts
due to our Chairman, President and Chief Executive
Officer. We repaid approximately $0.3 million and $0.4
million of an obligation we owed to Xu Jianping, our Chairman, President
and Chief Executive Officer, during the nine months ended September 30,
2010 and 2009, respectively.
|
|
·
|
Repayment
of note payable. We repaid in full our note payable under our loan
agreement with Guangzhou Rural Credit Cooperative in the second quarter of
2010, of which $731,294 was outstanding on the date of
repayment.
|
|
·
|
Amounts
due to a related company. The increase in due to a related company
for the nine months ended September 30, 2010 and 2009 was $4,184 and
approximately $0.2 million, respectively, which was attributable to the
increase in our obligations to the Guangdong Development Zone Hospital of
Qingyuan City.
|
25
Our
liquidity and cash flows are derived primarily from the operations of our
management company subsidiary, and specifically the management fees generated
from GDH and the other hospitals we may operate in the
future. According to the Exclusive Management Consultancy Agreement
between GDH and the management company, the management company is paid a monthly
management consultancy fee equal to the net profits of GDH, which is defined to
mean all its revenues, less its operating costs, expenses and
taxes. No fee is received if GDH does not generate a
profit. Also, even if GDH generates a profit, GDH may nevertheless be
unable to pay the management fee if it does not have sufficient disposable cash
on hand to do so. For example, GDH may record a profit from non-cash
items but there could be insufficient funds to pay the fee in whole or in part,
or the management company and GDH may determine that the profit should be
retained by GDH for operations. If we do not receive management fees from GDH in
full, it may result in a lack of liquidity and negatively affect our operations
and the growth of our company, as well as our ability to pay dividends to our
stockholders.
We
expect to improve our liquidity in the future by the following
approaches:
|
·
|
improving
GDH’s profitability;
|
|
·
|
acquiring
control of the operations of other hospitals, using a similar Exclusive
Management Consultancy Agreement arrangement;
and
|
|
·
|
to
raise funds through long-term debt and equity
financings.
|
Capital
Resources
We had
working capital of approximately $0.4 million as of September 30, 2010 and a
working capital deficit of approximately $0.1 million as of December 31,
2009. As a result of this working capital increase of approximately
$0.5 million, our working capital for the nine months ended September 30, 2010
was improved compared to the nine months ended September 30, 2009.
We are a
holding company with no significant revenue-generating operations of our own,
and thus any cash flows from operations are and will be generated by the
hospital that we operate, including through our management company’s existing
exclusive management arrangement with GDH. Our ability to service our
debt and fund ongoing operations is dependent on the results of these operations
and their ability to provide us with cash. The management company’s
ability to make loans or pay dividends are restricted under PRC law and may be
restricted under the terms of future indebtedness, its governing documents or
other agreements. Based upon the cash on hand, anticipated cash to be
received from our operations and the expected availability of cash from GDH’s
sole equity holder, we believe that our sources of liquidity will be sufficient
to enable us to meet our cash needs for at least the next 12
months. Our principal projected cash needs for the remainder of 2010
include the following components:
|
·
|
$7 million to acquire control of up
to three additional
hospitals;
|
|
·
|
$0.5 million in capital
expenditures related to GDH;
and
|
|
·
|
$0.5 million in working capital
and general business expenses to operate the
Company.
|
Except
for obligations for equipment described above and in connection with
acquisitions of control over additional hospitals, we have no material capital
commitments for the remainder of 2010. We continually monitor our
actual and forecasted cash position, as well as our liquidity and capital
resources, in order to plan for our current cash operating needs and to fund
business activities or new opportunities that may arise as a result of changing
business conditions. We intend to use our existing cash and cash
flows from operations to continue to grow our business, fund acquisitions of
hospital operations and pay existing obligations and any recurring capital
expenditures. Nonetheless, our liquidity and capital position could
be adversely affected by:
26
|
·
|
loss of revenue from patient
services and sales of
medicine;
|
|
·
|
delayed payment or non-payment of
receivables;
|
|
·
|
the enactment of new laws and
regulations;
|
|
·
|
our inability to grow our
business as we anticipate by expanding our existing hospital operations or
obtaining control of additional
hospitals;
|
|
·
|
any other changes in the cost
structure of our underlying business model;
and
|
|
·
|
any of the other risks and
uncertainties described in “Item 1A. Risk Factors” of our Form
10 registration statement.
|
For the
remainder of 2010, and continuing in 2011, we intend to seek to obtain a
long-term loan from one or more financial institutions to acquire control of two
additional hospitals, and we intend to seek to acquire control of another
hospital by obtaining additional equity capital. However, there can
be no assurance that our existing liquidity and capital resources will be
sufficient for our existing and proposed future operations and business plans or
that we will be able to obtain the bank loan or equity capital that we
seek. In such case, we would need to seek additional debt or
equity financings or to arrange for alternative sources of temporary or
permanent financing to meet our liquidity and capital
requirements. Our ability to obtain new financing could be adversely
impacted by, among other things, negative changes in our profitability and
restricted access to liquidity in the capital markets resulting from overall
economic conditions, as well as governmental regulations and restrictions in the
PRC that limit our ability to raise capital, and any changes in those
regulations. While we believe that we should be able to raise
additional debt or equity capital as the need arises, there can be no assurance
that we will be able to do so at a time when it is needed or at all, or that the
net proceeds from any such transactions will be sufficient to support our
operations or on terms that are favorable or acceptable to us. Any
inability to obtain future capital could materially and adversely affect our
business and growth plans, our results of operations and our liquidity and
financial condition.
Debt
Obligations
The table
below summarizes the amounts outstanding under our debt obligations as of
September 30, 2010 and December 31, 2009:
|
September
30,
2010
|
December
31,
2009
|
||||||
Loan
agreement note payable (including current portion)
|
$ | — | $ | 731,294 | ||||
Due
to stockholder
|
3,586,028 | 3,847,632 | ||||||
Due
to related company
|
205,756 | 201,572 | ||||||
Total
debt
|
$ | 3,791,784 | $ | 4,780,498 |
Loan
Agreement
As of
December 31, 2009, GDH borrowed RMB 5 million ($731,294) under a five-year, RMB
15 million loan agreement it entered with Guangzhou Rural Credit Cooperative in
September 2009. Loans made under this agreement bear interest at a
rate computed by reference to the published interest rates of the People’s Bank
of China for loans of the same term and grade. These interest rates
are adjusted on an annual basis. The interest rate on this loan was
6.34% per year. GDH’s obligations under the loan agreement were
secured by a mortgage on GDH’s hospital building and a personal guarantee by Mr.
Xu and his spouse. In the second quarter of 2010, we repaid all
amounts due under this loan agreement and we do not intend to borrow additional
amounts under this loan agreement.
27
Due
to Stockholder
As of
September 30, 2010 and December 31, 2009, we owed Mr. Xu, our Chairman,
President and Chief Executive Officer, $2,922 and $0.3 million, respectively,
under an interest-free, unsecured loan that is repayable on demand, and $3.6
million and $3.5 million, respectively, under an unsecured term loan due within
five years after January 1, 2011 with interest payable upon demand at 5% per
year.
Due
to a Related Company
As of
September 30, 2010 and December 31, 2009, GDH owed the Development Zone Hospital
$205,756 and $201,572 under an unsecured, interest-free loan that is
payable in installments ranging from December 31, 2008 to December 31,
2012. Mr. Xu is the President and a director of the Development Zone
Hospital, and Xu Jianhong, Mr. Xu’s brother, is the Executive Vice President and
a 30% shareholder of the Development Zone Hospital.
Other
Contractual Obligations
During
2010, we expect to incur future payments with respect to material contractual
obligations for cancer treatment equipment of $0.2 million.
Off-Balance
Sheet Arrangements
As of September 30, 2010, we did not
have any off-balance sheet obligations involving unconsolidated subsidiaries
that provide financing or potentially expose us to unrecorded financial
obligations. All of our obligations with respect to GDH have been
presented on our consolidated balance sheet.
Recently
Issued Accounting Pronouncements
Refer to
Note 1(F) of the Notes to Condensed Consolidated Financial Statements for a
description of recent accounting pronouncements including anticipated dates of
adoption and effects on our consolidated financial position and results of
operations.
Item
3. Quantitative and Qualitative Disclosures About Market
Risk.
Not
applicable to smaller reporting companies.
Item
4. Controls and Procedures.
Our
management, with the participation of our Chief Executive Officer and Chief
Financial Officer, conducted an evaluation of the effectiveness of our
disclosure controls and procedures, as defined in Rule 13a-15(e) under the
Securities Exchange Act of 1934, as amended, as of September 30,
2010. Based upon the September 30, 2010 disclosure controls
evaluation, our Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures were effective to provide a
reasonable level of assurance that information required to be disclosed in the
reports we file, furnish or submit under the Exchange Act is recorded,
processed, summarized and reported within the specified time periods in the
rules and forms of the Securities and Exchange Commission. These
officers have concluded that our disclosure controls and procedures were also
effective to provide a reasonable level of assurance that information required
to be disclosed in the reports that we file, furnish or submit under the
Exchange Act is accumulated and communicated to management, including the Chief
Executive Officer and Chief Financial Officer, to allow timely decisions
regarding required disclosure, all in accordance with Exchange Act Rule
13a-15(e). Our disclosure controls and procedures are designed to
provide reasonable assurance of achieving these objectives.
28
Our
management, with the participation of our Chief Executive Officer and Chief
Financial Officer, also conducted an evaluation of our internal control over
financial reporting, as defined in Exchange Act Rule 13a-15(f) and 15d-15(f), to
determine whether any changes occurred during the quarter ended September 30,
2010, that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting. Based on that
evaluation, there were no such changes during the quarter ended September 30,
2010.
Our
management, including our Chief Executive Officer and Chief Financial Officer,
does not expect that our disclosure controls and internal controls will prevent
all error and all fraud. A control system, no matter how well
conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the
design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their
costs. Because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that all control issues
and instances of fraud, if any, within the company have been
detected. These inherent limitations include the realities that
judgments in decision-making can be faulty and that breakdowns can occur because
of simple error or mistake. Additionally, controls can be
circumvented by the individual acts of some persons, by collusion of two or more
people or by management override of the controls.
PART
II - OTHER INFORMATION
Item
1. Legal
Proceedings.
We may be
involved in litigation and other legal proceedings from time to time in the
ordinary course of our business. Except as otherwise set forth in
this quarterly report, we believe the ultimate resolution of these matters will
not have a material effect on our financial position, results of operations or
cash flows.
Item
1A. Risk Factors.
There
have not been any material changes to the risk factors that were included in
Amendment No. 3 to our Form 10 registration statement filed with the SEC on
November 10, 2010.
Item
2. Unregistered Sales of Equity
Securities and Use of Proceeds.
There
were no issuances of our equity securities during the quarter ended September
30, 2010.
Limitations
on Our Payment of Dividends
We have
not paid any cash dividends to date and we do not anticipate or contemplate
paying dividends in the foreseeable future. It is the present
intention of management to utilize all available funds for the development of
our business.
In the
future, we may be a party to agreements that limit or restrict our ability to
pay dividends.
In
addition, Nevada corporate law prohibits us from making any distribution
(including a dividend) on our capital stock at a time when:
|
·
|
we
would not be able to pay our debts as they become due in the usual course
of business; or
|
|
·
|
our
total assets would be less than the sum of (i) our total liabilities plus
(ii) the amount that would be needed, if we were to be dissolved at the
time of distribution, to satisfy the preferential rights upon dissolution
of stockholders whose preferential rights are superior to those receiving
the distribution (although we presently do not have any stockholders with
such preferential rights).
|
The
management company is a wholly-foreign owned enterprise under the laws of the
PRC. The principal regulations governing dividend distributions by
wholly foreign owned enterprises and Sino-foreign equity joint ventures
include:
29
|
·
|
The
Wholly Foreign Owned Enterprise Law (1986), as
amended;
|
|
·
|
The
Wholly Foreign Owned Enterprise Law Implementing Rules (1990), as
amended;
|
|
·
|
The
Sino-foreign Equity Joint Venture Enterprise Law (1979), as amended;
and
|
|
·
|
The
Sino-foreign Equity Joint Venture Enterprise Law Implementing Rules
(1983), as amended.
|
Under
these regulations, wholly foreign owned enterprises and Sino-foreign equity
joint ventures in China may pay dividends only out of their accumulated profits,
if any, determined in accordance with PRC accounting standards and regulations.
Additionally, before paying dividends to their shareholders, these foreign
invested enterprises are required to set aside at least 10% of their profits
each year, if any, to fund certain reserve funds until the amount of the
cumulative total reserve funds reaches 50% of the relevant company’s registered
capital. Accordingly, the management company is allowed to distribute dividends
only after having set aside the required amount of its profits into the reserve
funds as required under applicable PRC laws and regulations.
Issuer
Repurchases of Equity Securities
During
the quarter ended September 30, 2010, we did not repurchase any of our shares of
our common stock.
Item
3. Defaults on Senior Securities.
Not applicable.
Item
4. Submission of Matters to a Vote of Security
Holders.
Not applicable.
Item
5. Other Information
Not applicable.
Item
6. Exhibits.
The
warranties, representations and covenants contained in any of the agreements
included herein or which appear as exhibits hereto should not be relied upon by
buyers, sellers or holders of the Company’s securities and are not intended as
warranties, representations or covenants to any individual or entity except as
specifically set forth in such agreement.
Exhibit
No.
|
Description
|
|
2.1
|
Share
Exchange Agreement, dated April 30, 2010, by and among China Dongfang
Healthcare Group Inc. Winmark Holdings Limited and each of the members of
Winmark Holdings Limited (1) (2)
|
|
3.1
|
Articles
of Incorporation of China Dongfang Healthcare Group Inc.
(2)
|
|
3.2
|
Bylaws
of China Dongfang Healthcare Group Inc. (2)
|
|
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934
|
|
31.2
|
Certification
of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934
|
|
32.1
|
Certification
of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
|
32.2
|
Certification
of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
30
(1)
|
Certain
exhibits and schedules to this agreement have been omitted pursuant to the
rules of the SEC. Omitted exhibits and schedules will be
provided supplementally to the SEC upon
request.
|
(2)
|
Incorporated
by reference to an exhibit to the Company’s Registration Statement on Form
10, as filed with the SEC on August 2, 2010 (File No.
0-54063).
|
31
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly
authorized.
CHINA
DONGFANG HEALTHCARE GROUP INC.
|
|||
Date:
November 15, 2010
|
By:
|
/s/ Xu Jianping
|
|
Xu
Jianping
|
|||
Chairman,
President and Chief Executive Officer
|
|||
|
|||
Date: November 15,
2010
|
By:
|
/s/ Wu Pifa
|
|
Wu
Pifa
|
|||
Chief
Financial Officer and
Treasurer
|
32
EXHIBIT
INDEX
Exhibit
No.
|
Description
|
|
2.1
|
Share
Exchange Agreement, dated April 30, 2010, by and among China Dongfang
Healthcare Group Inc. Winmark Holdings Limited and each of the members of
Winmark Holdings Limited (1) (2)
|
|
3.1
|
Articles
of Incorporation of China Dongfang Healthcare Group Inc.
(2)
|
|
3.2
|
Bylaws
of China Dongfang Healthcare Group Inc. (2)
|
|
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934
|
|
31.2
|
Certification
of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934
|
|
32.1
|
Certification
of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
|
32.2
|
Certification
of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
(1)
|
Certain
exhibits and schedules to this agreement have been omitted pursuant to the
rules of the SEC. Omitted exhibits and schedules will be
provided supplementally to the SEC upon
request.
|
(2)
|
Incorporated
by reference to an exhibit to the Company’s Registration Statement on Form
10, as filed with the SEC on August 2, 2010 (File No.
0-54063).
|
33